Report: U.K. academic R&D alliances are expensive but worth it
28 July 2015
A report commissioned by the United Kingdom government has found data to corroborate a widely held belief: R&D collaborations with British universities are expensive. Yet with such institutions performing world-class science--and tax breaks and funding schemes offsetting the upfront costs--Big Pharma is lining up to strike deals. Just ask Pfizer.
China state-owned drug firms move to direct consumer sales, prescriptions next?
28 July 2015
China's Shandong Freda Pharmaceutical Group has obtained a license to sell direct to consumers, China Daily reports, highlighting a trend that has gathered pace across over-the-counter remedies and healthcare products as companies also eye Beijing for a nod on ethical drugs.
Israeli biotechs scoop $209M as Nasdaq ATM keeps pumping out dollars
28 July 2015
A trio of Israeli biotechs have bagged $209 million (€192 million) through share offerings on Nasdaq. Chiasma ($CHMA) led the way with a $101.8 million IPO, trailed by follow-on offerings by NeuroDerm ($NDRM) and RedHill Biopharma ($RDHL) that pulled in $66.9 million and $40 million, respectively.
I'll prescribe it if you do: Prescribers susceptible to peer pressure, study finds
28 July 2015
Like teenage girls unsure of the latest fashion, doctors are susceptible to the social influence of their peers when it comes to prescribing both new and repeat drugs, according to a new Wharton School study. And not unlike said teens, peer influencers change over time. With doctors, however, the study found that the changes occur as a drug moves from new and risky to recurrent status.
UK aiming to match investment strategy to research timelines
27 July 2015
With the amount of funding available for biotech in the UK finally rebounding from the financial crisis, there is now a push to extend the timelines over which it is made available, to better accommodate the 10 to 15 years it takes to develop a drug.
Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar
27 July 2015
Biosimilar competition may take a bigger bite out of branded sales than we think. The top 10 biologics facing biosimilar competition will see sales fall to $49 billion by 2020, consensus estimates say. That's down from $62 billion last year. But according to Morningstar analysts, that 2020 sales number is too high.
Drugmakers like Gilead, Mylan and Novo--not Big Pharma--are job creators
27 July 2015
With a couple of exceptions, including 12% job growth at AstraZeneca ($AZN), little changed last year when it came to Big Pharma's employment numbers. But drop down to midtier players and the employment picture changes significantly, both in terms of how many jobs were added last year, and in one very notable case, how few.
Singapore's biopharma industry: Where the jobs are
24 July 2015
Hays Recruiting in Singapore says jobs in biopharma niches in manufacturing, regulatory and sales are up for grabs in the island nation, topping its latest quarterly regional outlook of skills in demand through September 2015, according to a press release.
Pharma needs to get into digital health data game to stay competitive, study says
24 July 2015
That Apple ($APPL) watch you are wearing may allow you to text and listen to music, and it can track your activity. But it may also be conducting a postmarket study that will help cut the price of some of your prescription drugs in the future.
Novartis CEO predicts a pharma pricing squeeze from insurer M&A
24 July 2015
Worried that health insurers' urge to merge will put even more pressure on your prices? You're in good company. Novartis ($NVS) CEO Joe Jimenez agrees. For years, pricing freedom in the U.S. has allowed drugmakers to set prices higher than in other countries and raise them along the way. The tactics help offset budget pressures overseas and can drive sales growth for meds on the decline.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024